Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + lenalidomide + rituximab versus placebo + lenalidomide + rituximab in relapsed/refractory follicular lymphoma or marginal zone lymphoma
NL-OMON60464Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafasitamab, lenalidomide and rituximab in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL), sponsored by Incyte. Primary endpoint: Progression-free survival in follicular lymphoma population. Started Sep 2021; status: active, not recruiting.
02
Drugs
tafasitamablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NL-OMON60464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60464.